Drug recall · January 18, 2023
Rifampin Capsules USP recall
Why: Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Rifampin Capsules USP, 300 mg, 30-count bottle; Rx Only, Manufactured for: Lupin Pharmaceuticals Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India. NDC 68180-659-06
- Lots / codes
Lot # A200171, Exp 12/2023
- Quantity
- 16,056 30 count bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Distributed Nationwide in the USA
- Initiated
- December 12, 2022 · Voluntary: Firm initiated
- Classified
- January 9, 2023
- Reported
- January 18, 2023
- Ended
- January 31, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Rifampin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.